Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Novartis Pharmaceuticals
Woman and Man Max 99 years
Novartis Pharmaceuticals Corporation
Update Il y a 4 ans
A double-blind, randomized, multi-center active-controlled, parallel-group study comparing the combination of valsartan 320 mg plus hydrochlorothiazide 12.5 mg and valsartan 320 mg plus hydrochlorothiazide 25 mg to valsartan 320 mg in mild to moderate hypertensive patients not adequately controlled with valsartan 320 mg
To demonstrate the blood pressure reduction effect of valsartan/HCTZ 320/25 mg o.d. or 320/12.5 mg o.d. in patients with mild to moderate hypertension not adequately controlled with valsartan 320 mg ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Man Max 99 years
Novartis Pharmaceuticals UK Ltd
Update Il y a 4 ans
An Open label Randomised, multicentre study to evaluate the efficacy of two Zometa (Zoledronic acid) schedules on bone mineral density in prostrate cancer patients undergoing Androgen deprivation Therapy (ADT)
The primary objective of this study is to compare the effect of intravenous Zometa® (zoledronic acid) 4 mg administered every 12 weeks (arm 1) versus every 24 weeks (arm 2) on bone loss associated wi...
Country
None
organs
None
Specialty
None
unknown
More information
Woman Max 99 years
Novartis Pharmaceuticals
Update Il y a 4 ans
Feasibility of Doctors' Rooms-based Infusion of Zoledronic Acid
1. The study will assess the safety and tolerability of a single-infusion of zoledronic acid 5 mg administered in a private medical practice setting by a nurse provided by a nati...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharmaceuticals UK Ltd
Update Il y a 4 ans
An extension to a phase II study to determine the efficacy and safety of STI571 in patients with chronic myeloid leukemia who are refractory to or intolerant of interferon-alpha
•To enable patients to have access to study drug and continue study treatment •To decrease data collection to include overall survival and serious adverse events
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Novartis Pharmaceuticals UK Ltd
Update Il y a 4 ans
Extension to a multicenter, open label study to assess the safety and efficacy of 600 micrograms SOM230, administered subcutaneously, b.i.d. in patients with Cushing's disease
To assess the long-term efficacy of SOM230 in patients with Cushing’s disease
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharmaceuticals, Japan
Update Il y a 4 ans
SPP100 Dose Finding Study in Japan
This study will evaluate the efficacy of SPP100 in lowering blood pressure in patients with essential hypertension.
Country
Japan
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharmaceuticals Corporation
Update Il y a 4 ans
Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients
To assess the safety of ICL670 compared to deferoxamine during 24 weeks in patients with sickle cell disease and iron overload from repeated blood transfusion.
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Novartis Pharmaceuticals Corporation
Update Il y a 4 ans
A study comparing Tobramycin Inhalation Powder (TIP) administered once daily continuously versus TIP administered BID in 28 day on / 28 day off cycles for the treatment of pulmonary Pseudomonas aeruginosa in patients with cystic fibrosis
To provide efficacy and safety data comparing two dosing schedules of Tobramycin Inhalation Powder (TIP) for the treatment of pulmonary Pseudomonas aeruginosa in patients with cystic fibrosis.
Country
None
organs
None
Specialty
None
More information
Woman and Man Max 99 years
Novartis Pharmaceuticals, Japan
Update Il y a 6 ans
Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)
To provide efficacy and safety data of two doses (0.5 mg and 1.25 mg) of FTY720 in Japanese patients with relapsing multiple sclerosis (MS)
Country
Japan
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Novartis Pharmaceuticals UK Ltd
Update Il y a 4 ans
Safety and efficacy study of INC424 in patients with myelofibrosis
To evaluate the efficacy of daily oral doses of 15mg BID or 20mg BID of INC424 in patients with PMF, PPV-MF, or PET-MF, based on the proportion of patients experiencing treatment success at the 48 wee...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
Next